Review anchor
Homeodomain-interacting protein kinase 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Homeodomain-interacting protein kinase 2
CHEMBL4576
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Homeodomain-interacting protein kinase 2 as ChEMBL target CHEMBL4576, mapped to UniProt Q9H2X6. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL4576
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9H2X6
Homeodomain-interacting protein kinase 2
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Homeodomain-interacting protein kinase 2 matters
Homeodomain-interacting protein kinase 2 is reviewed as Homeodomain-interacting protein kinase 2 (UniProt Q9H2X6); the current evidence base includes 11 approved drugs, 1423 compounds, and 311 assays, with lead potency reaching pChEMBL 8.4.
Protein context
Homeodomain-interacting protein kinase 2
Homeodomain-interacting protein kinase 2 Sequence length is 1198 aa.
Review this target as Homeodomain-interacting protein kinase 2, mapped to UniProt Q9H2X6. Sequence length is 1198 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q9H2X6
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 11 approved drugs, 1423 compounds, and 311 assays for this target. The dominant activity type is KI. CHEMBL1997554 is the current potency anchor at pChEMBL 8.4.
Use CHEMBL1997554 as the tractability anchor when discussing potency (pChEMBL 8.4).
Activity source · ChEMBL 36 via Core Engine
11 approved
pChEMBL 8.4
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Homeodomain-interacting protein kinase 2 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9H2X6, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1423
Total Compounds
311
Total Assays
11
Approved Drugs
IC50: 105.0, KI: 696.0, KD: 85.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1997554
|
8.4 | Ki | — |
|
|
No preferred name
CHEMBL4750420
|
8.3 | IC50 | — |
|
|
No preferred name
CHEMBL1983932
|
8.2 | Ki | — |
|
|
No preferred name
CHEMBL1987448
|
8.2 | Ki | — |
|
|
No preferred name
CHEMBL243298
|
8.2 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
FEDRATINIB
CHEMBL1287853
|
2019 |
|
|
ABEMACICLIB
CHEMBL3301610
|
2017 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
RUXOLITINIB
CHEMBL1789941
|
2011 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
|
|
SORAFENIB
CHEMBL1336
|
2005 |
Source Header